BDX Shares Struggle Despite Q1 Earnings Beat: What You Need to Know
Based in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) stands as a prominent player in medical technology striving to enhance healthcare. The company boasts a market cap of $64.5 billion and develops groundbreaking medical devices, diagnostic solutions, and biosciences tools that aid healthcare providers, laboratories, and life sciences researchers.
Stock Performance Overview
Over the past year, Becton, Dickinson and Company’s shares have not kept pace with the broader market. Specifically, BDX has decreased 5.8%, while the S&P 500 Index ($SPX) has gained 22.3%. In 2025, the medtech stock showed a slight decline, whereas SPX posted a YTD gain of 4%.
Comparative Analysis with Medical Device Sector
When looking closer, BDX stock also trails behind the iShares U.S. Medical Devices ETF’s (IHI) 14.3% rise in the last 52 weeks and a 10.3% increase year-to-date.
Recent Earnings Report Highlights
Following its Q1 earnings report on February 5, Becton, Dickinson and Company’s shares fell 7.3%. The adjusted EPS rose by 28% year-over-year to $3.43, which exceeded Wall Street’s estimate of $2.98. Furthermore, revenue climbed 9.8% to $5.17 billion, topping consensus forecasts. The company raised its fiscal 2025 guidance, projecting adjusted EPS between $14.30 and $14.60, indicating a potential 10% growth at the midpoint.
Future Earnings Expectations
For the ongoing fiscal year ending in September 2025, analysts predict BDX’s EPS to grow 9.8% year-over-year to $14.43. Notably, the company has a strong track record of earnings surprises, beating consensus estimates in all of the last four quarters.
Analyst Ratings and Price Targets
Among the 17 analysts monitoring the stock, there’s a consensus rating of “Strong Buy.” This includes 14 “Strong Buy” recommendations, one “Moderate Buy,” and two “Holds.”
Price Target Changes
The rating has remained stable over the recent months. On February 14, Barclays adjusted BDX’s price target to $279 from $278, retaining an “Overweight” rating. The average price target of $274.73 suggests an upside potential of about 22.2%, while the highest target price of $305 indicates a possible rally of up to 35.7%.
On the date of publication, Rashmi Kumari did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. For more information, please see the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
